

FINANCIAL TEAR SHEET

CORPORATE PROFILE

iRhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. Our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ECG, monitoring for patients at risk for arrhythmias.


We have created a unique platform, ZIO by iRhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.

STOCK INFORMATION

IRTC (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$40.25
Change (%)	▼ 0.36 (0.89%)
Volume	170,797
52 Week Low	\$22.16
Market Cap	\$902,693,253
Rolling EPS	-3.89
PE Ratio	0
Shares Outstanding	22,228,349

Data as of 06/27/17 1:07 p.m. ET



RECENT NEWS

Date	Title
06/21/17	New Expert Statement Recognizes Patch Monitors Such as Zio by iRhythm as Effective for Atrial Fibrillation Monitoring Post-Ablation
05/18/17	New Study Confirms Extended Continuous Cardiac Monitoring is More Efficient than Holter Monitoring for Cryptogenic Stroke Patients
05/03/17	iRhythm Technologies Announces First Quarter 2017 Financial Results

UPCOMING EVENTS

There are currently no events scheduled.

SEC FILINGS

Filing Date	Form
06/16/17	8-K
06/12/17	SC 13G/A
06/09/17	4
06/09/17	SC 13G/A

Data provided by Nasdaq. Minimum 15 minutes delayed.